Author:
Mostaghim Anahita,Sathe Neha A.,Mabrey F. Linzee,Sahi Sharon,O'Connor Nick,Morrell Eric D.,Fitzpatrick Michael,Smith Craig H.,Wurfel Mark M.,Liles W. Conrad,Bhatraju Pavan K.
Reference7 articles.
1. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Emergency and Critical Care Group, ed;Ghosn;Cochrane Database Syst Rev,2021
2. Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence. Cochrane Haematology Group, ed;Wagner;Cochrane Database Syst Rev,2022
3. Association of inflammatory biomarker abnormalities with mortality in COVID-19: a meta-analysis;Suri;Bull Natl Res Cent,2022
4. Plasma Interleukin-6 predicts clinical decline after completion of dexamethasone therapy in severe COVID-19;Mabrey;Crit Care Explor,2022
5. Remdesivir for the treatment of Covid-19 — final report;Beigel;N Engl J Med,2020